| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7223387 | BAUSCH | Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
Nov, 2022
(10 months ago) | |
Xerese is owned by Bausch.
Xerese contains Acyclovir; Hydrocortisone.
Xerese has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Xerese are:
- US7223387
Xerese was authorised for market use on 31 July, 2009.
Xerese is available in cream;topical dosage forms.
Xerese can be used as new combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolescents (12 years of age and older); combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).
The generics of Xerese are possible to be released after 13 November, 2022.
Drugs and Companies using ACYCLOVIR; HYDROCORTISONE ingredient
Market Authorisation Date: 31 July, 2009
Treatment: New combination product for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and adolesc...
Dosage: CREAM;TOPICAL
XERESE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic